Detalhe da pesquisa
1.
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
Prostate
; 78(6): 435-445, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29431193
2.
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells.
Clin Chem
; 64(3): 536-546, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301749
3.
Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography.
J Pers Med
; 12(5)2022 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35629148
4.
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 25(6): 1766-1773, 2019 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209161